Health Care & Life Sciences » Biotechnology | CytomX Therapeutics Inc.

CytomX Therapeutics Inc.

CytomX Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
44.96 M
Public Float
32.4 M
CytomX Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.91
Market Cap
$508.84 M
Shares Outstanding
45.31 M
Public Float
43.69 M

Profile

Address
151 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.cytomx.com
Updated 07/08/2019
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W.

Financials

View All

Sean A. McCarthy
President, Chief Executive Officer & Director
Ho Young Huh
Chairman